Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

Transcriptase Inhibitor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients

HIV Medicine ◽

10.1111/j.1468-1293.2005.00315.x ◽

2005 ◽

Vol 6 (6) ◽

pp. 388-395 ◽

Cited By ~ 3

Author(s):

L Cuzin ◽

P Pugliese ◽

F Bugnon ◽

C Delpierre ◽

E Cua ◽

...

Keyword(s):

Reverse Transcriptase ◽

Prospective Cohort ◽

Transcriptase Inhibitor ◽

First Line ◽

Therapy Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(19)30036-2 ◽

2019 ◽

Vol 19 (3) ◽

pp. 253-264 ◽

Cited By ~ 39

Author(s):

Michael Aboud ◽

Richard Kaplan ◽

Johannes Lombaard ◽

Fujie Zhang ◽

José A Hidalgo ◽

...

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Inhibitor Therapy ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Reverse Transcriptase Inhibitor ◽

Hiv 1

Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic

HIV Clinical Trials ◽

10.1310/hct1005-306 ◽

2009 ◽

Vol 10 (5) ◽

pp. 306-313 ◽

Cited By ~ 7

Author(s):

G.J. Dragovic ◽

C.J. Smith ◽

D.J. Jevtovic ◽

M.A. Johnson ◽

J. Ranin ◽

...

Keyword(s):

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings

Journal of the International AIDS Society ◽

10.7448/ias.19.1.20978 ◽

2016 ◽

Vol 19 (1) ◽

pp. 20978

Author(s):

Viviane D Lima ◽

Mark Hull ◽

David McVea ◽

William Chau ◽

P Richard Harrigan ◽

...

Keyword(s):

Transcriptase Inhibitor ◽

First Line ◽

Resource Limited Settings ◽

First Line Therapy ◽

Line Therapy ◽

Resource Limited ◽

Therapy Choice ◽

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen

HIV Medicine ◽

10.1111/hiv.12144 ◽

2014 ◽

Vol 15 (9) ◽

pp. 547-556 ◽

Cited By ~ 6

Author(s):

I Jarrin ◽

B Hernández-Novoa ◽

B Alejos ◽

I Santos ◽

J Lopez-Aldeguer ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

First Line ◽

Cohort Comparison ◽

Drug Regimens ◽

Observational Cohort ◽

Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial

AIDS ◽

10.1097/qad.0b013e32832d9031 ◽

2009 ◽

Vol 23 (12) ◽

pp. 1605-1608 ◽

Cited By ~ 11

Author(s):

Cathia Soulié ◽

Lambert Assoumou ◽

Jade Ghosn ◽

Claudine Duvivier ◽

Gilles Peytavin ◽

...

Keyword(s):

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor–based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials

Clinical Infectious Diseases ◽

10.1093/cid/ciw236 ◽

2016 ◽

Vol 63 (2) ◽

pp. 268-280 ◽

Cited By ~ 10

Author(s):

Álvaro H. Borges ◽

Andreas Lundh ◽

Britta Tendal ◽

John A. Bartlett ◽

Nathan Clumeck ◽

...

Keyword(s):

Systematic Review ◽

Hiv Infection ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Initial Treatment ◽

Randomized Trials ◽

Transcriptase Inhibitor ◽

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(10)70313-3 ◽

2011 ◽

Vol 11 (4) ◽

pp. 273-283 ◽

Cited By ~ 88

Keyword(s):

Viral Load ◽

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Transcriptase Inhibitor ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Initial highly-active antiretroviral therapy with a protease inhibitor versus a nonnucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect metaanalyses

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70040-3 ◽

2007 ◽

Vol 2007 ◽

pp. 61-62

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Highly Active Antiretroviral Therapy ◽

Transcriptase Inhibitor ◽

Highly Active ◽

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing nonnucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: openlabel randomised trial

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70039-7 ◽

2007 ◽

Vol 2007 ◽

pp. 60-61

Author(s):

D.R. Snydman

Keyword(s):

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Randomised Trial ◽

Transcriptase Inhibitor ◽